| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/30/2002 | US6425881 Therapeutic mixture useful in inhibiting lesion formation after vascular injury |
| 07/30/2002 | CA2344707C N-substituted cycloalkyl and polycycloalkyl alpha-substituted trp-phe- and phenethylamine derivatives |
| 07/30/2002 | CA2291067C Method for the preparation of citalopram |
| 07/30/2002 | CA2228997C Benzothiophene compounds |
| 07/30/2002 | CA2217157C Inhibition of c. difficile infections by indigestible oligosaccharides |
| 07/30/2002 | CA2209714C A controlled release formulation for poorly soluble basic drugs |
| 07/30/2002 | CA2119351C Phosphoramidate analogs of 5-fluoro-2'-deoxyuridine |
| 07/30/2002 | CA2110806C 4-(1h-pyrrol-1-yl)imidazoles with angiotensin ii antagonist activity |
| 07/30/2002 | CA2107896C Method and composition for treating hyperproliferative skin diseases using 6-aminopurine cytokinins |
| 07/30/2002 | CA2104461C Therapeutic compositions to protect and resuscitate mammalian cells and methods for preparing and using same |
| 07/30/2002 | CA2079777C Oligonucleotide analogs |
| 07/30/2002 | CA2075291C Anti-tumor agent derived from dextrane |
| 07/30/2002 | CA2072081C Polyhemoglobin stabilized by purine derivatives and glutathione |
| 07/30/2002 | CA2067614C Agent for improving dementia |
| 07/30/2002 | CA2062428C Low dose dry pharmaceutical preparations |
| 07/30/2002 | CA2060490C Protection from shock subsequent to injury by double-stranded rnas |
| 07/30/2002 | CA2056619C Method of inactivation of viral and bacterial blood contaminants |
| 07/30/2002 | CA2045433C Low molecular weight polysaccharide mixes; process for their preparation and use |
| 07/30/2002 | CA2039052C Process for preparing piroxicam/cyclodextrin complexes, the products obtained and their pharmaceutical compositions |
| 07/26/2002 | CA2369264A1 Method of treating certain cancers using an estrogen agonist/antagonist |
| 07/25/2002 | WO2002058323A2 Method for identifying modulators of bace |
| 07/25/2002 | WO2002057790A2 Methods and compositions for diagnosing and treating a subject having depression |
| 07/25/2002 | WO2002057492A1 Methods and compositions for detecting polynucleotide duplex damage |
| 07/25/2002 | WO2002057489A2 Method of determining a chemotherapeutic regimen based on ercc1 and ts expression |
| 07/25/2002 | WO2002057474A2 Processes for enhanced production of pantothenate |
| 07/25/2002 | WO2002057473A1 Method for inhibiting vegf and epo gene expression by quercetin |
| 07/25/2002 | WO2002057465A2 Method for producing polyunsaturated fatty acids, novel biosynthesis genes and novel plant expression constructs |
| 07/25/2002 | WO2002057425A2 Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
| 07/25/2002 | WO2002057409A2 Antisense modulation of src-2 expression |
| 07/25/2002 | WO2002057327A1 Method of preparing poly(vinyl pivalate) |
| 07/25/2002 | WO2002057302A2 A virus causing respiratory tract illness in susceptible mammals |
| 07/25/2002 | WO2002057298A2 C-terminal modified oxamyl dipeptides as inhibitors of the ice/ced-3 family of cysteine proteases |
| 07/25/2002 | WO2002057288A1 Novel acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same |
| 07/25/2002 | WO2002057287A2 Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
| 07/25/2002 | WO2002057285A1 Fullerene derivative and composition comprising the same |
| 07/25/2002 | WO2002057275A1 Boron-containing nicotine analogs for use in the treatment of cns pathologies |
| 07/25/2002 | WO2002057274A1 A process for the synthesis of atorvastatin form v and phenylboronates as intermediate compounds |
| 07/25/2002 | WO2002057273A1 Serine protease inhibitors comprising a hydrogen-bond acceptor |
| 07/25/2002 | WO2002057271A2 Thienopyrimidine-based inhibitors of the src family |
| 07/25/2002 | WO2002057270A1 Inhibitors of cruzipain and other cysteine proteases |
| 07/25/2002 | WO2002057269A1 Synthesis of temozolomide and analogs |
| 07/25/2002 | WO2002057268A1 Synthesis of temozolomide and analogs |
| 07/25/2002 | WO2002057267A1 Compounds specific to adenosine a1, a2a, and a3 receptor and uses thereof |
| 07/25/2002 | WO2002057264A1 Pyrrole derivates for treating cytokine mediated diseases |
| 07/25/2002 | WO2002057261A2 Diaminothiazoles and their use as inhibitors of cyclin-dependent kinase |
| 07/25/2002 | WO2002057260A1 Compounds for use in the treatment of skin conditions |
| 07/25/2002 | WO2002057259A2 Pyrazole compounds useful as protein kinase inhibitors |
| 07/25/2002 | WO2002057256A1 Piperazinylcarbonylquinolines and -isoquinolines |
| 07/25/2002 | WO2002057253A2 Isoindolyl and isoquinolinyl aroyl pyrrole compounds for the treatment of central nervous system disorders |
| 07/25/2002 | WO2002057252A2 Heterocyclic sulfonamide inhibitors of beta amyloid production |
| 07/25/2002 | WO2002057250A1 Tetrahydropyran derivatives as neurokinin receptor antagonists |
| 07/25/2002 | WO2002057249A1 Cyclic 2-carbonylaminoketones as inhibitors of cruzipain and other cysteine proteases |
| 07/25/2002 | WO2002057248A2 Inhibitors of cruzipain and other cysteine proteases |
| 07/25/2002 | WO2002057246A2 Inhibitors of cruzipain and other cysteine proteases |
| 07/25/2002 | WO2002057242A2 Urea derivatives as integrin alpha 4 antagonists |
| 07/25/2002 | WO2002057240A1 Substituted triazole diamine derivatives as kinase inhibitors |
| 07/25/2002 | WO2002057239A2 Pyrimidine phosphorylase as a target for imaging and therapy |
| 07/25/2002 | WO2002057238A1 Substituted quinolines for the treatment of protozoan and retrovirus co-infections |
| 07/25/2002 | WO2002057236A1 Phenyl derivatives |
| 07/25/2002 | WO2002057233A1 Mch antagonists and their use in the treatment of obesity |
| 07/25/2002 | WO2002057231A2 Benz(g) indoles and their use as spla2 inhibitors |
| 07/25/2002 | WO2002057230A1 Il-8 receptor antagonists |
| 07/25/2002 | WO2002057229A1 FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN) |
| 07/25/2002 | WO2002057224A2 Synthesis and antimicrobial activityof novel dicationic 'reversed amidines' |
| 07/25/2002 | WO2002057222A2 Thiol-based naaladase inhibitors |
| 07/25/2002 | WO2002057219A1 Novel 1,2-diphenylethene derivatives for treatment of immune diseases |
| 07/25/2002 | WO2002057218A1 Alanine 2,6-dialkoxyphenyl ester derivatives as hypnotics |
| 07/25/2002 | WO2002057215A2 Sodium channel modulators |
| 07/25/2002 | WO2002057212A1 Retinol derivatives and process for preparing same |
| 07/25/2002 | WO2002057211A1 Symmetrically disubstituted aromatic compounds and pharmaceutical compositions for inhibiting poly (adp-ribose) glycohydrolase, and methods for their use |
| 07/25/2002 | WO2002056964A1 Use of flumazenil in developing a drug for the treatment of alcohol dependence |
| 07/25/2002 | WO2002056941A2 Method for the treatment of peripheral vascular disease |
| 07/25/2002 | WO2002056915A2 Complex of modafinil and cyclodextrin |
| 07/25/2002 | WO2002056914A1 Injections for endoscopy |
| 07/25/2002 | WO2002056913A2 Stabilized brivudine topical formulations containing metal oxide pigments |
| 07/25/2002 | WO2002056912A2 Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent |
| 07/25/2002 | WO2002056911A1 Transplantation rejection inhibitors |
| 07/25/2002 | WO2002056904A1 Biocatalytic and biomimetic generation of nitric oxide in situ at substrate/blood interfaces |
| 07/25/2002 | WO2002056903A2 Methods for treating hormone associated conditions using a combination of lhrh antagonists and specific estrogen receptor modulators |
| 07/25/2002 | WO2002056902A2 Ccr5 antagonist and dp-178 polypeptide for treating viral infections |
| 07/25/2002 | WO2002056899A1 Compositions and methods for reducing oxysterols in blood |
| 07/25/2002 | WO2002056895A2 Ionene polymers and their use in treating mucositis |
| 07/25/2002 | WO2002056894A1 Promoting cell regeneration and/or cell differentiation with non-metabolizable sugar and a polymeric absorbent |
| 07/25/2002 | WO2002056893A1 Novel receptors for $i(helicobacter pylori) and use thereof |
| 07/25/2002 | WO2002056892A2 Methods of treating neurological disorders |
| 07/25/2002 | WO2002056891A1 Regulation of glucocorticoid concentration |
| 07/25/2002 | WO2002056890A1 Novel method and compositions for local treatment of meniere's disease, tinnitus and/or hearing loss |
| 07/25/2002 | WO2002056888A2 Assay method, tnf modulator and its use |
| 07/25/2002 | WO2002056887A1 New combination of active ingredients containing alfuzosine and apomorphine |
| 07/25/2002 | WO2002056886A1 Angiogenesis inhibitors contaiing urea derivative as the active ingredient |
| 07/25/2002 | WO2002056885A1 Camptothecin derivatives |
| 07/25/2002 | WO2002056884A2 Treatment of malaria with farnesyl protein transferase inhibitors |
| 07/25/2002 | WO2002056883A1 Preparation of micron-size felodipine particles by microfluidization |
| 07/25/2002 | WO2002056882A1 Quinolines and nitrogenated derivaive thereof substituted in 4-position by a piperidine-containing moiety and their use as antibacterial agents |
| 07/25/2002 | WO2002056881A1 Fenofibrate tablets |
| 07/25/2002 | WO2002056880A1 Triphenylmethane kinesin inhibitors |
| 07/25/2002 | WO2002056879A1 Use of terpenes for the treatment of digestive tract infections |
| 07/25/2002 | WO2002056878A2 Pharmaceutical composition having reduced tendency for drug crystallization |
| 07/25/2002 | WO2002056877A1 Treatment of sleep disturbances |
| 07/25/2002 | WO2002056876A2 Treatment for snoring |